Find the latest IGM Biosciences, Inc. (IGMS) stock quote, history, news and other vital information to help you with your stock trading and investing.

4 天之前 · A high-level overview of IGM Biosciences, Inc. (IGMS) stock. View (IGMS) real-time stock price, chart, news, analysis, analyst reviews and more.

2025年1月10日 · On Friday, Truist Securities revised its price target for IGM Biosciences (NASDAQ: IGMS) shares, significantly reducing it to $2.00 from the previous $12.00 while maintaining a Hold rating on the...

2025年3月21日 · Get a real-time IGM Biosciences, Inc. (IGMS) stock price with an overview of financials, statistics, forecasts, charts and more.

Get the latest IGM Biosciences, Inc. (IGMS) stock news and headlines to help you in your trading and investing decisions.

2024年10月2日 · 公司指出，将优先开发其主要候选药物 **imvotamab**，这是一种具有治疗类风湿性关节炎、狼疮和肌炎潜力的 CD20 x CD3 T 细胞结合剂，以及 **IGM-2644**，一种 CD38 x CD3 T 细胞结合剂，计划于今年晚些时候开始针对重症肌无力的 I 期临床试验。 与此同时，公司将减少在 **aplitabart** 和其他肿瘤学项目上的支出，包括裁员，以将资金储备维持到 2027 年。 IGM 从肿瘤学转向免疫学，特别是狼疮的举措，与今年早些时候其他多家细胞治疗生物技术公司（ …

The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will tar...

Six Sigma (6σ) is a set of techniques and tools for process improvement. It was introduced by American engineer Bill Smith while working at Motorola in 1986. [1][2] Six Sigma strategies seek to improve manufacturing quality by identifying and removing the causes of defects and minimizing variability in manufacturing and business processes.

MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with...

IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. The company halted cancer trials, reduced its...